Literature DB >> 10571201

The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy.

L R Prosnitz1, P Maguire, J M Anderson, S P Scully, J M Harrelson, E L Jones, M Dewhirst, T V Samulski, B E Powers, G L Rosner, R K Dodge, L Layfield, R Clough, D M Brizel.   

Abstract

PURPOSE: To explore the use of a novel program of preoperative radiation and hyperthermia in the management of high-grade soft tissue sarcomas (STS). METHODS AND MATERIALS: Eligible patients were adults over 18 with Grade 2 or 3 STS, surgically resectable without a local excision prior to referral to Duke University Medical Center and without distant metastases. Patients were staged generally with CT and/or MR imaging. The diagnosis was established with fine needle aspiration or incisional biopsy. Patients were then treated with 5000 to 5040 cGy, 180-200 cGy per fraction. Chemotherapy was usually not employed. Generally two hyperthermia treatments per week were given with a planned thermal dose of 10-100 CEM 43 degrees T90. Invasive thermometry and thermal mapping were done in all patients. Surgical resection was planned 4-6 weeks after the completion of radiation and hyperthermia.
RESULTS: Ninety-seven patients were treated on study between 1984 and 1996. Follow-up ranged from 12 to 155 months (median 32). All tumors were high-grade in nature, 44 greater than 10 cm in size (maximum tumor diameter), 43 5-10 cm in size, 10 less than 5 cm. Seventy-eight of the 97 tumors were located in an extremity. Of the 97 patients, 48 remain alive and continually free of disease following initial therapy. Of the remaining 49 patients, 44 have relapsed (34 dead, 10 living with disease), 3 have died secondary to complications of therapy, and 2 have died of unrelated causes. Ten-year actuarial overall survival, cause-specific survival, and relapse-free survival are 50, 47, and 47% respectively. The predominant pattern of failure has been distant metastases with only 2 patients developing local failure alone. Ten-year actuarial local control for extremity tumors is 94%, 63% for the 19 patients with tumors at sites other than the extremity. Of the 78 patients with extremity lesions, 63 have had limb preservation and remain locally controlled. Overall 38 patients experienced 57 major complications. There were 3 deaths, one due to adriamycin cardiomyopathy and two secondary to wound infections. Four patients required amputation secondary to postoperative wound healing problems. Complications directly attributable to hyperthermia occurred in 15 patients with 11 instances of second- or third-degree burns and two instances of subcutaneous fat necrosis. The hyperthermia complications were generally not severe and either healed readily or were excised at the time of surgical resection of the primary tumor.
CONCLUSIONS: For these aggressive high-grade soft tissue sarcomas, this treatment program of preoperative thermoradiotherapy provided excellent local regional control for extremity lesions (95%) and satisfactory local regional control (63%) of nonextremity sarcomas, but did not appear to influence the rate of distant metastases or survival. Complications were frequent but apart from the direct thermal burns, not too different from those reported for preoperative radiotherapy alone. More effective adjuvant systemic therapy is necessary to impact favorably on survival.

Entities:  

Mesh:

Year:  1999        PMID: 10571201     DOI: 10.1016/s0360-3016(99)00272-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Radiotherapy and wound healing.

Authors:  Emma-Louise Dormand; Paul E Banwell; Timothy E E Goodacre
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

Review 2.  Hyperthermia: How Can It Be Used?

Authors:  Zhaleh Behrouzkia; Zahra Joveini; Behnaz Keshavarzi; Nazila Eyvazzadeh; Reza Zohdi Aghdam
Journal:  Oman Med J       Date:  2016-03

3.  Accuracy of real time noninvasive temperature measurements using magnetic resonance thermal imaging in patients treated for high grade extremity soft tissue sarcomas.

Authors:  Oana I Craciunescu; Paul R Stauffer; Brian J Soher; Cory R Wyatt; Omar Arabe; Paolo Maccarini; Shiva K Das; Kung-Shan Cheng; Terence Z Wong; Ellen L Jones; Mark W Dewhirst; Zeljko Vujaskovic; James R MacFall
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

Review 4.  Hyperthermia in soft tissue sarcoma.

Authors:  Lars H Lindner; Rolf D Issels
Journal:  Curr Treat Options Oncol       Date:  2011-03

Review 5.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer.

Authors:  Eduardo G Moros; Jose Peñagaricano; Petr Novàk; William L Straube; Robert J Myerson
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 6.  Molecular parameters of hyperthermia for radiosensitization.

Authors:  Tej K Pandita; Shruti Pandita; Sukesh R Bhaumik
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

7.  Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.

Authors:  F Eckert; C Gani; T Kluba; F Mayer; H-G Kopp; D Zips; M Bamberg; A-C Müller
Journal:  Strahlenther Onkol       Date:  2013-04-21       Impact factor: 3.621

8.  Significance of local treatment in patients with metastatic soft tissue sarcoma.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Dongrong Situ; Han Yang; Yuanfang Li; Hao Long; Zhiwei Zhou
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

9.  A retrospective study of SBRT of metastases in patients with primary sarcoma.

Authors:  Christina Linder Stragliotto; Kristin Karlsson; Ingmar Lax; Eva Rutkowska; Jonas Bergh; Hans Strander; Henric Blomgren; Signe Friesland
Journal:  Med Oncol       Date:  2012-07-20       Impact factor: 3.064

10.  Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment.

Authors:  D K Kelleher; O Thews; A Scherz; Y Salomon; P Vaupel
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.